Spinillo A, Colonna L, Piazzi G, Baltaro F, Monaco A, Ferrari A
Department of Obstetrics and Gynecology, University of Pavia, IRCCS Policlinico S. Matteo, Italy.
J Reprod Med. 1997 Feb;42(2):83-7.
To evaluate the efficacy of one-day, intermittent, monthly prophylaxis with 400 mg itraconazole in the management of recurrent vulvovaginal candidiasis.
In a randomized trial, 57 patients and 57 controls with recurrent vulvovaginal candidiasis were assigned either to receive one-day monthly itraconazole prophylaxis for six months or no treatment. Clinical and mycologic evaluations were carried out 3, 6 and 12 months after enrollment.
During the first six months of follow-up, the rate of symptomatic recurrences was 36.4% (20/55) among the treated women and 64.2% (34/53) in the controls. The mean time +/- SEM to symptomatic recurrence was 149 +/- 6 days among patients receiving prophylaxis and 120 +/- 6 days in the controls (P = .003 by log-rank test). These differences disappeared almost completely after the cessation of intermittent prophylaxis. In fact, the proportion of patients still asymptomatic after one year of follow-up was 38.9% (21/54) among treated women and 28.8% (15/53) in the controls (P = .83 by Fisher's exact test).
One-day monthly, intermittent itraconazole prophylaxis reduced the rate of recurrence in patients with recurrent vulvovaginal candidiasis, but the beneficial effect of itraconazole was lost within a few months after cessation of prophylaxis.
评估每月一日间歇服用400毫克伊曲康唑预防复发性外阴阴道念珠菌病的疗效。
在一项随机试验中，57例复发性外阴阴道念珠菌病患者和57例对照者被分配接受为期六个月的每月一日伊曲康唑预防治疗或不接受治疗。在入组后3、6和12个月进行临床和真菌学评估。
在随访的前六个月中，接受治疗的女性中有症状复发率为36.4%（20/55），对照组为64.2%（34/53）。接受预防治疗的患者出现症状复发的平均时间±标准误为149±6天，对照组为120±6天（对数秩检验P = 0.003）。在间歇预防治疗停止后，这些差异几乎完全消失。事实上，随访一年后仍无症状的患者比例在接受治疗的女性中为38.9%（21/54），对照组为28.8%（15/53）（Fisher精确检验P = 0.83）。
每月一日间歇服用伊曲康唑预防可降低复发性外阴阴道念珠菌病患者的复发率，但在预防治疗停止后的几个月内，伊曲康唑的有益作用就消失了。
